FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Wedbush raised their FY2028 earnings per share (EPS) estimates for shares of Disc Medicine in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $7.04 per share for the year, up from their prior estimate of $6.85. Wedbush has a “Outperform” rating and a $83.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Several other analysts have also issued reports on IRON. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a report on Tuesday, November 5th. HC Wainwright upped their price target on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research report on Wednesday. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $66.00 to $110.00 in a research report on Monday, November 4th. Finally, Wells Fargo & Company started coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price on the stock. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine has a consensus rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Stock Performance

Shares of IRON stock traded down $0.21 during mid-day trading on Thursday, reaching $62.85. 5,334 shares of the company’s stock traded hands, compared to its average volume of 354,763. The firm has a market capitalization of $1.87 billion, a PE ratio of -15.84 and a beta of 0.60. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The firm has a 50 day moving average price of $50.81 and a two-hundred day moving average price of $44.64.

Insider Buying and Selling at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 7,538 shares of company stock worth $437,875 in the last quarter. 4.24% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRON. Amalgamated Bank boosted its holdings in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the second quarter valued at $129,000. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the third quarter valued at $131,000. Finally, Quantbot Technologies LP bought a new stake in shares of Disc Medicine in the 3rd quarter worth about $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.